Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILAUDID-HP vs FLORINEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydromorphone is a full mu-opioid receptor agonist with high affinity for mu-opioid receptors, producing analgesia, euphoria, and sedation. It also binds to kappa and delta opioid receptors with lower affinity.
Fludrocortisone is a synthetic corticosteroid with predominantly mineralocorticoid activity, promoting sodium retention and potassium excretion in the distal renal tubules, thereby increasing extracellular fluid volume and blood pressure.
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate (FDA-approved),Off-label: Treatment of acute pain, postoperative pain, cancer pain, and breakthrough pain
Partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease,Salt-losing congenital adrenal hyperplasia,Postural hypotension (off-label)
Initial dose: 0.2-0.6 mg IV/IM/SC every 2-4 hours as needed; usual adult dose: 0.2-0.4 mg IV/IM/SC. Oral: 1-2 mg every 3-6 hours. Dose titration based on pain severity.
0.1 mg orally once daily, with range 0.1-0.2 mg/day. Dose may be divided twice daily if needed.
Terminal elimination half-life: 2.3–4 hours. In clinical context, consistent with dosing interval of 4–6 hours for immediate-release formulations; prolonged in hepatic or renal impairment.
Terminal elimination half-life: 3.5 hours; clinical effect half-life due to mineralocorticoid activity is longer (~12-24 hours), allowing once-daily dosing.
Hydromorphone is extensively metabolized in the liver via glucuronidation to hydromorphone-3-glucuronide (major metabolite) and to a lesser extent via reduction to dihydroisomorphine and dihydromorphine. Minor CYP2C9 and CYP3A4 involvement.
Primarily hepatic via CYP3A4-mediated metabolism; also metabolized by 11β-hydroxysteroid dehydrogenase to inactive metabolites.
Renal: predominantly as hydromorphone-3-glucuronide (H3G), unchanged hydromorphone (<6%), and other metabolites. Biliary/fecal: minimal.
Renal: ~80% as metabolites, ~20% unchanged; minimal biliary/fecal elimination.
Approximately 20–30%, primarily to albumin.
~90% bound to corticosteroid-binding globulin (CBG) and albumin.
1.2–1.8 L/kg. Indicates extensive tissue distribution, consistent with a lipophilic opioid.
Vd: ~0.3 L/kg; distributes mainly into extracellular fluid and binds to renal mineralocorticoid receptors.
Oral: 24–51% (first-pass metabolism); Intramuscular: 96% (relative to IV).
Oral: ~100% (well absorbed); no significant first-pass metabolism.
GFR 30-60 m L/min: reduce dose by 25-50%; GFR 10-29 m L/min: administer 50-75% of normal dose every 6-8 hours; GFR <10 m L/min: administer 25-50% of normal dose every 8-12 hours.
No specific dose adjustment recommended based on GFR; use with caution in severe renal impairment due to sodium retention.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce initial dose by 50%; Child-Pugh Class C: avoid use or reduce dose by 75% with extended dosing interval.
No specific adjustment for Child-Pugh; monitor for fluid overload in severe hepatic impairment.
Children >2 years: 0.1-0.2 mg/kg IV/IM/SC every 4-6 hours; maximum single dose 2 mg. Neonates/infants: 0.03-0.05 mg/kg IV/IM/SC every 4-6 hours.
0.05-0.1 mg orally once daily; titrate based on response.
Initial dose: 0.1-0.2 mg IV/IM/SC every 4-6 hours; reduce dose by 50% compared to younger adults; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Initiate at lower dose (0.05 mg daily) and titrate slowly; monitor for hypertension, hypokalemia, and fluid overload.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISKS OF USE IN PATIENTS WITH HEAD INJURY OR INCREASED INTRACRANIAL PRESSURE.
None
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion,Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Adrenal insufficiency,Severe hypotension,Gastrointestinal effects (constipation, ileus),Seizures,Withdrawal
May cause sodium retention and edema, especially in patients with cardiac disease,Monitor for hypokalemia and hyperglycemia,Increased risk of infections due to immunosuppression,May mask symptoms of infection,Do not use in patients with systemic fungal infections,Avoid abrupt discontinuation after prolonged therapy due to risk of adrenal insufficiency
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to hydromorphone or any component of the product
Systemic fungal infections,Hypersensitivity to fludrocortisone or any component of the formulation,Concurrent live or attenuated virus vaccines (relative)
Avoid alcohol while taking DILAUDID-HP, as it can potentiate CNS depression and increase the risk of respiratory depression. Grapefruit juice may inhibit CYP2D6 and CYP3A4 metabolism, potentially increasing hydromorphone levels; avoid concurrent consumption. High-fat meals may delay absorption; maintain consistent timing with or without food.
Avoid excessive licorice (glycyrrhizin) which can enhance mineralocorticoid effects and worsen hypokalemia. Maintain a low-sodium diet to reduce fluid retention and hypertension. Increase potassium-rich foods if not contraindicated.
FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies have shown teratogenicity at high doses. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid use during labor due to risk of neonatal respiratory depression.
Fludrocortisone (Florinef) is a corticosteroid with mineralocorticoid activity. In animal studies, corticosteroids have been associated with cleft palate and other malformations. Human data are limited. First trimester exposure may slightly increase risk of oral clefts. Second and third trimester use may suppress fetal adrenal function, leading to neonatal adrenal insufficiency. Overall risk is low with short-term use, but chronic high doses should be avoided.
Hydromorphone is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 2.6. Limited data suggest low levels, but use caution due to potential for infant sedation and respiratory depression. The American Academy of Pediatrics considers hydromorphone compatible with breastfeeding if used short-term at low doses.
Fludrocortisone is excreted into breast milk in small amounts. The milk-to-plasma ratio is unknown. At typical doses, the amount ingested by the infant is likely to be low and not expected to cause adverse effects. However, monitor infant for signs of adrenal suppression. Use with caution, especially with high maternal doses.
Pregnancy does not significantly alter hydromorphone pharmacokinetics, but dose adjustments may be needed due to increased pain or opioid tolerance. Use lowest effective dose for shortest duration. Monitor for respiratory depression and adjust accordingly.
Pharmacokinetic changes in pregnancy (increased volume of distribution, increased renal clearance) may reduce fludrocortisone levels, potentially requiring dose adjustment to maintain desired effect. Dose should be titrated based on clinical response (e.g., blood pressure, electrolyte levels). No specific dosing guidelines; individualize therapy.
DILAUDID-HP (high-potency hydromorphone) is indicated for opioid-tolerant patients only; 1 mg DILAUDID-HP is equivalent to 4 mg standard hydromorphone. Use with extreme caution in patients with respiratory compromise, COPD, or cor pulmonale. Avoid in patients with paralytic ileus or suspected GI obstruction. Monitor for serotonin syndrome when co-administered with serotonergic drugs. For PCA use, ensure proper programming to prevent overdose. Naloxone is the reversal agent; may require higher doses due to high potency.
Monitor for signs of edema, hypertension, and hypokalemia. Use lowest effective dose. Caution in patients with heart failure, hypertension, or renal impairment. Do not abruptly discontinue; taper slowly. May interfere with cortisol assays.
This is a high-potency opioid; take exactly as prescribed and never increase dose without consulting your doctor.,Do not break, crush, or chew tablets; swallow whole to avoid rapid release of the drug.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they can increase the risk of severe drowsiness, respiratory depression, and death.,Do not stop taking abruptly; withdrawal symptoms may occur. Consult your doctor for a tapering plan.,Constipation is a common side effect; maintain adequate fluid intake, fiber, and consider stool softeners or laxatives as needed.,Store securely out of reach of children and pets; properly dispose of unused medication at a take-back location.,Seek emergency medical attention if you experience difficulty breathing, extreme drowsiness, confusion, or fainting.,This medication may impair your ability to drive or operate machinery; avoid such activities until you know how it affects you.
Take exactly as prescribed; do not stop suddenly without doctor's advice.,Weigh yourself daily and report rapid weight gain or swelling.,Monitor blood pressure regularly.,Eat a low-salt diet to help control fluid retention.,Report signs of high potassium (muscle weakness, irregular heartbeat) or low potassium (cramps, fatigue).,Carry medical ID indicating you take fludrocortisone.,Avoid excessive licorice intake (can worsen potassium loss).,May cause increased thirst and urination.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILAUDID-HP vs FLORINEF, answered by our medical review team.
DILAUDID-HP is a Opioid Analgesic that works by Hydromorphone is a full mu-opioid receptor agonist with high affinity for mu-opioid receptors, producing analgesia, euphoria, and sedation. It also binds to kappa and delta opioid receptors with lower affinity.. FLORINEF is a Corticosteroid (Mineralocorticoid) that works by Fludrocortisone is a synthetic corticosteroid with predominantly mineralocorticoid activity, promoting sodium retention and potassium excretion in the distal renal tubules, thereby increasing extracellular fluid volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILAUDID-HP and FLORINEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILAUDID-HP is: Initial dose: 0.2-0.6 mg IV/IM/SC every 2-4 hours as needed; usual adult dose: 0.2-0.4 mg IV/IM/SC. Oral: 1-2 mg every 3-6 hours. Dose titration based on pain severity.. The standard adult dose of FLORINEF is: 0.1 mg orally once daily, with range 0.1-0.2 mg/day. Dose may be divided twice daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILAUDID-HP and FLORINEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILAUDID-HP is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies have shown teratogenicity at high doses. Second and third trimesters: Chronic maternal u. FLORINEF is classified as Category C. Fludrocortisone (Florinef) is a corticosteroid with mineralocorticoid activity. In animal studies, corticosteroids have been associated with cleft palate and other malformations. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.